ImpediMed |
High $0.20 |
Low $0.18 |
Trades 151 |
Turnover $593,932 |
Volume 3,225,766 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (16-Nov) $14,663,997 (564th) |
Close (30-Jun) $0.180 |
Volume (30-Jun) 3,225,766 |
Shortsold (2-Jul) 99,795 (0.00%) (657th) |
|
52w High $0.041 |
52w Low $0.003 |
P/E - |
EPS -0.01 |
AstraZeneca extends and increases Renal Contract
IPD released this announcement to the ASX on 18 March 2022, 10:23. The announcement is marked as price sensitive, and is 3 page(s) in length and 268.95kb in size.
You can view all announcements from IPD and see how they appear on a price chart on the announcements page.
At the date of this announcement, IPD was 0.444% short sold according to ASIC data. It was ranked the 318th most shorted stock on the ASX. It remains ranked 657th as of the latest reported data (02 July 2026).
| Other Recent Announcements from IPD | |
|---|---|
| Revised Security Trading Policy | 30 June 2023, 8:18 |
| ImpediMed Achieves Critical Mass in First Key Target State | 29 June 2023, 9:32 |
| ImpediMed Updates Board for Growth in Oncology | 28 June 2023, 8:22 |
| AstraZeneca extends and increases Renal Contract | 18 March 2022, 10:23 |
| Bone Data Presented, Strong Correlation between SOZO and DXA | 7 March 2022, 8:24 |
| S&P DJI Announces March 2022 Quarterly Rebalance | 4 March 2022, 17:02 |
| Appendix 4D and Interim Financial Report | 25 February 2022, 8:04 |
If you were already registered, log in here.